Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions
|
|
- Eustace Nelson
- 5 years ago
- Views:
Transcription
1 Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions Friday, December 8, 2017 Atlanta, Georgia Friday Satellite Symposium preceding the 59th ASH Annual Meeting & Exposition. This activity is supported by educational grants from Amgen, Celgene Corporation, Janssen, Karyopharm, Takeda Oncology, and The Binding Site. Image: Copyright 2017 DNA Illustrations. All Rights Reserved
2 Discussion 4 Therapeutic Strategies After First Relapse Following Initial Therapy Presented by Jesús F. San-Miguel, MD, PhD
3 Presenting Faculty Jesús F. San-Miguel, MD, PhD Director of Clinical and Transnational Medicine Clinica Universidad de Navarra Universidad de Navarra Pamplona, Spain Jesús F. San-Miguel, MD, PhD, has disclosed that he has received consulting fees from Amgen, Bristol- Myers Squibb, Celgene, Janssen, MSD, Novartis, Takeda, Sanofi-Aventis, and Roche.
4 Program Director Brian G.M. Durie, MD Co-Chair Myeloma Committee, SWOG Chairman, International Myeloma Foundation Specialist in Multiple Myeloma and Related Disorders Cedars-Sinai Outpatient Cancer Center Los Angeles, California Brian G.M. Durie, MD, has disclosed that he has received consulting fees from Celgene, Johnson & Johnson, Amgen, and Takeda.
5 Patient Case 4 A 60-year-old man was diagnosed with IgD lambda, stage II myeloma, and t(4;14) He received VTD for 3 cycles followed by ASCT and 2 years of lenalidomide maintenance He relapsed 18 months after discontinuing lenalidomide maintenance
6 How would you treat this patient? Expert Brian G.M. Durie, MD Philippe Moreau, MD Bruno Paiva, PhD Recommendation Treatment with a CD38 antibody combination until progression Rescue treatment followed by second ASCT or Treatment with a CD38 antibody combination until progression Treatment with a CD38 antibody combination until progression S. Vincent Rajkumar, MD Rescue treatment followed by second ASCT or Treatment with a CD38 antibody combination until progression Jesús F. San-Miguel, MD, PhD Rescue treatment followed by second ASCT or Treatment with a CD38 antibody combination until progression
7 Strategies at Relapse: How to Make the RIGHT CHOICE? Disease-related factors Type of relapse, cytogenetic risk, extramedullary disease Efficacy and toxicity of previous treatments Patient-related factors Age (Trx eligibility), comorbidities, frailty Further options
8 60-Year-Old Man Relapsing after VTD + ASCT + Len x 2y: How to Make the RIGHT CHOICE? Decisions based on the duration of the previous response Early relapse (< 1 year post ASCT) Overcome drug resistance Combination of non cross-resistant agents VTD (KRD)-PACE + Dara RIC-Allo Intermediate relapse (1-3 years post ASCT) Prolong survival until curative treatments are developed Sequential novel agent combinations: Dara + PomDex..KRD... Late relapse (> 3 years post ASCT) Aggressive relapse: Reinduction (KRD + Dara) + 2nd ASCT Biochemical relapse: Repeat the initial approach or same as above
9 Patient Case 5 A 72-year-old man was diagnosed with an IgA, stage I myeloma, and moderate renal insufficiency He was initially treated with a bortezomib-based VMP for 9 cycles and achieved VGPR that lasted for 2 years
10 How would you treat this patient at first relapse? Expert Brian G.M. Durie, MD Philippe Moreau, MD Bruno Paiva, PhD Recommendation Daratumumab/lenalidomide/dexamethasone Daratumumab/lenalidomide/dexamethasone Daratumumab/lenalidomide/dexamethasone S. Vincent Rajkumar, MD Daratumumab/lenalidomide/dexamethasone Jesús F. San-Miguel, MD, PhD Daratumumab/lenalidomide/dexamethasone
11 72y Man 1st/2nd Relapse Following Bortezomib Induction (VMP/VCD) Without lenalidomide maintenance: Lenalidomide/Dexamethasone until progression (PFS 15 m) but Triplets (with RD as backbone)* KRD (PFS 26.3 m) 1 IRD (PFS 20.6 m) 2 EloRD (PFS 19.4 m) 3 DaraRD (NR) 4 Economical constrains RD + Cyclophosphamide VTD ( if TFI > 12m) 1. Stewart AK, et al. NEJM 2015;372: Moreau P, et al. NEJM 2016;374: Lonial S, et al. NEJM 2015;373: Dimopoulos MA, et al. NEJM 2016;375:
12 Triplets with Len-Dex Combinations in Relapsed MM: Survival in Phase III Trials Carfilzomib ASPIRE trial (KRd vs Rd) 1 : CR: 31.8% vs 9.3% PFS: 26.3 vs 17.6 months (HR 0.69, P = ) 8.7 months OS: 48 vs 40 months 2 (HR 0.79, P =.01). 8 months Ixazomib TOURMALINE MM1 trial (IRd vs Rd) 3 : CR: 11.7% vs 6.6% PFS: 20.6 vs 14.7 months (HR 0.74, P = 0.01) 5.9 months IRd, ixazomib + lenalidomide + dexamethasone; KRd, carfilzomib +lenalidomide + dexamethasone. 1. Stewart AK, et al. N Engl J Med 2015;372: Stewart AK, et al. ASH Abstract Moreau P, et al. NEJM 2016;374:
13 Carfilzomib ASPIRE trial (KRd vs Rd): Overall survival Proportion surviving without progression KRd Rd Number of subjects at risk: KRd Rd HR (95% CI) = ( ) Death n (%) Median OS months HR for KRd vs Rd (95% CI) Months since randomization KRd (n = 396) 246 (62.1) 48.3 Rd (n = 396) 267 (67.4) ( ) 1-sided P = Stewart AK, et al. ASH Abstract 743. Stewart et al ASH 2017, Abstract 743
14 Carfilzomib-Len-Dex (KRd) in Relapsed MM Phase III ASPIRE Trial: Safety Profile Data KRd Rd Treatment discontinuation due to AE, % Grade 3 Anemia, % Neutropenia, % Thrombocytopenia, % Peripheral neuropathy, % Cardiac failure, % Ischemic heart disease, % Cardiovascular impact of CFZ in MM: Baseline elevated cardiac peptides and abnormal cardiac strain (60% at baseline) A rise in the NT-proBNP occurs immediately after Cfz based chemotherapy 5% of severe cardiac events attributable to cfz Stewart AK, et al. ASH Abstract 79, oral presentation. Stewart AK, et al. N Engl J Med 2015;372: Rosenthal AC, et al. ASH Abstract 4748, poster presentation.
15 Tourmaline-MM1: Ixazomib +/- RD: Safety Increased Rates with IRd Driven by Low-Grade Events IRd (N = 361), % Placebo-Rd (N = 359), % Preferred terms All-grade Grade 3-4 All-grade Grade 3-4 AEs overlapping with lenalidomide Diarrhea Nausea Rash* Upper respiratory tract infection 23 < 1 19 < 1 Thrombocytopenia AEs with proteasome inhibitors Peripheral neuropathy* Peripheral edema AEs with lenalidomide Thromboembolism* Neutropenia* *Represents multiple MedDRA preferred terms. Moreau P, et al. N Engl J Med 2016;374:
16 Monoclonal Antibodies in Multiple Myeloma Direct effects Alterations in intracellular signalling Inhibition of growth factor receptor function Inhibition of adhesion molecule function Activation of complement system Complement-dependent cytotoxicity (CDC) Activation of macrophages Antibody-dependent cell-mediated phagocytosis (ADCP) Activation of natural killer (NK) cells Antibody-dependent cellular cytotoxicity (ADCC) - Elotuzumab (Anti-SLAMF7) - Single Agent: 26% SD - Anti-CD38: Daratumumab * & Isatuximab - Single agent: 30-35% ORR Depletes CD38-expressing immunosuppressive regulatory cells (myeloid derived suppressor cells and regulatory T and B cells), which in turn promotes T-cell expansion and activation and increased T-cell clonality van de Donk NW et al. Blood 2016;127:681-95
17 Elotuzumab + Len/Dex (Eloquent-2): Extended PFS and OS ORR (ELd vs Ld): 79% vs 66% VGPR: 32.7% vs 27.9% Probability progression free year PFS 2-year PFS 3-year PFS PFS (months) No. of patients at risk: E-Ld Ld PFS 1 (19.4 vs 14.9 m) OS 2 (43.7 vs 39.6 m) % 57% % reduction in risk of disease progression or death PFS: 19.4 vs 14.9 HR 0.73 (95% CI 0.60, 0.89) P = % 27% % 18% E-Ld Ld Probability alive OS (months) 1. Lonial S, et al. N Engl J Med 2015;373: Dimopoulos MA, et al. Br J Haematol. 2017;178: No. of patients at risk: E-Ld Ld year OS 2-year OS 3-year OS 91% % % 69% OS: 43.7 vs 39.6 months HR 0.77 (95% CI ) P = % 53% E-Ld Ld 0 0
18 Elotuzumab + Len + Dex in RRMM Phase III Eloquent Trial: Results Treatment Grade 3 AEs, % ELd (n = 464) Ld (n = 465) Fatigue, % 9 8 Neutropenia, % Thrombocytopenia, % Anemia, % Infusion reactions, % 11% grade 1/2 1% grade 3 - Addition of elotuzumab did not increase the incidence of AE compared to Len/Dex alone. - 70% of infusion reactions occur with the first dose. - Only 2 patients discontinue the study due to an infusion reaction. Lonial S, ASCO Abstract Dimopoulos MA, ASH 2015 oral presentation 28. NA
19 % surviving without progression Daratumumab-Len-Dex (DRd) vs Len-Dex (Rd) in Relapsed MM Phase III POLLUX trial ORR: 93% vs 76% CR: 51% vs 21% Median follow-up of 25.4 months PFS (ITT) HR, 0.41 (95% CI, ; P < ) 24-month PFS 68% 41% Months DRd (n = 286) Median not reached Rd (n = 283) Median 17.5 mo Dimopoulos MA, et al. NEJM 2016;375: Bahlis NZ, et al. Poster presentation at ASCO Abstract MRD-negative rate (%) MRD 6 DRd 13 DRd Rd DRd Rd DRd Rd Rd
20 Daratumumab-Len-Dex (DRd) vs Len-Dex (Rd) in Relapsed MM Phase III POLLUX trial Dara-Rd All AEs Grade 3/4 AEs All AEs Grade 3/4 AEs Neutropenia 59% 52% 43% 37% Diarrhea 43% 5% 25% 3% Upper respiratory tract infection 32% 1% 21% 1% Fatigue 35% 6% 28% 3% Anemia 31% 12% 35% 20% Constipation 29% 1% 25% 1% Thrombocytopenia 27% 13% 27% 14% Infections 28% 23% Treatment discontinuation due to AEs 7% 8% DRd was associated with a manageable safety profile consistent with the known safety profile of D and Rd. Dimopoulos MA, et al. NEJM 2016;375: Rd
21 72y Man 1st /2nd Relapse Following Bortezomib Induction (VMP/VCD) Without lenalidomide maintenance: Lenalidomide/Dexamethasone until progression (PFS 15 m) but Triplets (with RD as backbone)* KRD (PFS 26.3 m) 1 IRD (PFS 20.6 m) 2 EloRD (PFS 19.4 m) 3 DaraRD (NR) 4 Economical constrains RD + Cyclophosphamide VTD ( if TFI > 12m) 1. Stewart AK, et al. NEJM 2015;372: Moreau P, et al. NEJM 2016;374: Lonial S, et al. NEJM 2015;373: Dimopoulos MA, et al. NEJM 2016;375:
22 Lenalidomide-Cyclophosphamide-Prednisone Phase I/II trial in LEN-REFRACTORY Patients Phase I: define MTD (n = 21)...Expansion Phase: ORR, CBR, PFS, & OS (n = 61) Lenalidomide 25 mg Days Cyclo 50 mg/day + Predn 20 mg/day (28-day cycle) Patient population: > 1 prior line + lenalidomide refractory Median nº prior lines: 3 (1 10), 66% Bort-refractory ORR 67%; VGPR 23%; CR 5% (1 scr) Median PFS: 12.1 m Median OS: 29.0 m Median FUP: 24.5 m Nijhof I, et al. Blood 2016;128: Nijhof I, et al. Blood 2016;128(19):
23 72-Yr-Old Man 1 st /2 nd Relapse Following VRD Induction Pomalidomide (4 mg x D1-21) + Cyclophosphamide (300 mg per wk) + Dexamethasone (2 pulses 40 mg) in 28 day cycle in relapsing patients treated with IFM2009/DFCI trial protocol: VRD (induction & consolidation) followed by 1-Yr len maintenance (arm A) or ASCT after induction (arm B) N = 90 patients: ORR 91% (2% CR, 32% VGPR) after 4 cycles Garderet, et al. ASH Abstr 837. Pomalidomide + Dex..Addition of Cyclophosphamide 500 mg D1, 15 (iv) if < PR on Cycle 3 in patients with R/R MM after 2 prior tx lines including bortezomib and lenalidomide N = 60 patients..36 pts refractory (16 PD, 15 SD, 5 MR): 13 (32%) achieved at least PR, with median PFS from start of cyclophosphamide of 5 months Weisel K, et al. ASH Abstr 1849.
24 Patient Case 6 A 82-year-old woman was diagnosed with an IgGk, stage III myeloma, and deletion p53 in 20% of PC She achieved a VGPR with lenalidomide/dexamethasone On month 24 of continuous treatment, she developed rapid disease progression
25 How would you treat this patient now? Expert Brian G.M. Durie, MD Philippe Moreau, MD Bruno Paiva, PhD Recommendation Daratumumab/bortezomib/dexamethasone Daratumumab/bortezomib/dexamethasone Daratumumab/bortezomib/dexamethasone S. Vincent Rajkumar, MD Daratumumab/bortezomib/dexamethasone Jesús F. San-Miguel, MD, PhD Daratumumab/bortezomib/dexamethasone
26 82-Year-Old Woman First or Second Relapse Following continuous Lenalidomide Dexa (Lenalidomide refractory)* Bortezomib-Dex (PFS: 9.4 m) Carfilzomib-Dex (PFS: 18.7 m) 1 Triplets based on bortezomib: EloVD (PFS: 9.7 m) 2 DaraVd (60.7% 12-m PFS) 3 PanobinostatVd (PFS: 12 m) 4 Economical Constrains VMP/VCD (16 m; 83% at 1 Yr) 5,6 * If she was on len maintenance : the previous mentioned triplets (VTD, KRD) could be considered 1. Dimopoulos MA, et al. Lancet Oncol. 2016;17: Jakubowiak A, et al. Blood. 2016;127: Palumbo A, et al. N Engl J Med. 2016;375: San Miguel JF, et al. Lancet Oncol 2014;15: Reece DE, et al. JCO 2008;26: Reece DE, et al. Clin Lymphoma Myeloma Leuk. 2016;16:
27 Carfilzomib-Dex vs Bortezomib-Dex in RMM Phase III ENDEAVOR Trial: PFS and OS Data Primary Endpoint: PFS 1 Secondary Endpoint: OS 2 Proportion Surviving Without Progression Kd Vd Kd Vd Events, n Median PFS, mo HR (95% CI) 0.53 ( ) P < Months Since Randomization Proportion Surviving Kd Vd Death n (%) Median OS months HR for Kd vs Vd (95% CI) Kd (n = 464) Months Since Randomization Vd (n = 465) 189 (40.7) 209 (44.9) ( ) 1-sided P = ORR (Kd vs Vd): 77% vs 63%. CR: 13% vs 6% Median DOR (Kd vs Vd): 21.3 vs 10.4 months 1. Dimopoulos MA, et al. Lancet Oncol. 2016;17: Dimopoulos MA, et al. Lancet Oncol. 2017;18:
28 Dara-Vd vs Vd in Relapsed MM (Castor) Updated efficacy % surviving without progression Median follow-up of 19.4 months 100 ITT month PFS a 48% HR: % (95% CI, ; P <0.0001) Months DVd (n = 251) Median 16.7 mo Vd (n = 247) Median 7.1 mo SOC, standard of care. a Kaplan-Meier estimates; exploratory analyses based on 1-year update: clinical cut-off date of January 11, ORR, % CR 29% ORR = 84% 9% 20% 35% 22% P < CR 10% VGPR 62% ORR = 63% 3% 7% 19% 34% DVd (n = 240) Vd (n = 234) VGPR 29% scr CR VGPR PR 1. Lentzsch S et al. Poster presentation at ASCO Abstract 8036.
29 Daratumumab- Carfilzomib- Dexamethasone 85 Patients : all exposed to PI & IMIDs and 60% refractory to Len Dara: 16 mg/k C1-2/w, C3-6/2w, C7./4w; K: C1D1: 20 mg/m 2 and C1D8: 70; weekly D1,8,15 Dex: 40 mg/w ORR: 84%; PFS at 12-m: 74 % Lonial S, ASH 2017 Abstract 1869
30 PANORAMA 1: Panobinostat + Bort + Dex vs Bort + Dex ORR PanoBD vs PcboBD: 60.7% vs 54.6% CR: 27.6% vs 15.7% PFS Probability, % Median PFS(m) PAN-BTZ-Dex Pbo-BTZ-Dex PFS PAN-BTZ-Dex Pbo-BTZ-Dex 12 ( ) 8.1 ( ) HR (95% CI) 0.63 ( ) Number of patients at risk Months PAN-BTZ-Dex Pbo-BTZ-Dex No benefit in OS PFS Probability, % Subgroup Analysis by Prior Treatment: PFS Prior BTZ + IMiDs w/ 2 Prior Lines Median PFS(m) PAN-BTZ-Dex (n/n = 44/73) Pbo-BTZ-Dex (n/n = 54/74) PAN-BTZ-Dex Months Number of Patients at Risk PAN-BTZ-Dex Pbo-BTZ-Dex Pbo-BTZ-Dex 12.5 ( ) 4.7 ( ) HR (95% CI) 0.47 ( ) San Miguel JF et al. Lancet Oncol. 2014;15(11):
31 82-Year-Old Woman First or Second Relapse Following continuous Lenalidomide Dexa (Lenalidomide refractory)* Bortezomib-Dex (PFS: 9.4 m) Carfilzomib-Dex (PFS: 18.7 m) 1 Triplets based on bortezomib: EloVD (PFS: 9.7 m) 2 DaraVd (60.7% 12-m PFS) 3 PanobinostatVd (PFS: 12 m) 4 Economical Constrains VMP/VCD (16 m; 83% at 1 Yr) 5,6 * If she was on len maintenance : the previous mentioned triplets (VTD, KRD) could be considered 1. Dimopoulos MA, et al. Lancet Oncol. 2016;17: Jakubowiak A, et al. Blood. 2016;127: Palumbo A, et al. N Engl J Med. 2016;375: San Miguel JF, et al. Lancet Oncol 2014;15: Reece DE, et al. JCO 2008;26: Reece DE, et al. Clin Lymphoma Myeloma Leuk. 2016;16:
32 82-Year-Old Woman: First Relapse or Primary Refractory VCD (/21d x 8 cycles) vs KCD (/28d x 6): Btz 1.3 mg biweekly, K 20/36 mg; cyclo 550 mg/w, Dex: 40 mg/w Patients: 99 vs 201 in first relapse or refractory ORR 68% vs 84% ( VGPR: 32 vs 40%) PN ( 8,6 vs 0,7%) Cardiac ( 1,4 vs 4%) Kwee Young, et al. ASH Abstr 835. VCD (/35d x 9 cycles) vs LCD (/28d x 9): Btz 1.3 mg/w L: 25 mg; cyclo 550 mg D 1,8, Dex: 40 mg/w Patients: 77 vs 77 in first relapse ORR 68% vs 84% (VGPR: 16% vs 20%); PFS: 16 vs 20 m ; OS: 31 vs 36 m Motefusco, et al. ASH Abstr 836.
33 What Are the Factors Influencing Our Decisions? Age Type of relapse Number/Types of prior lines of therapy Cytogenetic abnormalities
34 Would Advanced Age Modify Our Strategy? Impact of AGE PFS HR (95% CI) POLLUX (DRd vs Rd) 1 ASPIRE (KRd vs Rd) 2 ELOQUENT (ERd vs Rd) 3 TOURMALINE (IRd vs Rd) 4 ENDEAVOR (Kd vs Vd) 5 CASTOR (DVd vs Vd) 6 < 65y 65 y < 65y 65 y < 65y 65 y < 65y y < 75y 75 y < 65y 65 y 0.4 ( ) 0.4 ( ) 0.60 ( ) 0.74 ( ) 0.75 ( ) 0.65 ( ) ( ) 0.35 ( ) Favors novel-agent 1. Dimopoulos MA, et al. NEJM 2016;375: Stewart AK, et al. N Engl J Med 2015;372: Lonial S et al, NEJM 2015 Aug 13;373(7): Moreau P et al. N Engl J Med. 2016;374: Dimopoulos MA, et al. Lancet Oncology 2016; 17: Palumbo A et al, NEJM 2016; 6. Moreau P, ASH 2015 abst
35 What Are the Factors Influencing Our Decisions?: Prior Lines of Therapy HR (95% CI) POLLUX (DRd vs Rd) 1 ASPIRE (KRd vs Rd) 2 ELOQUENT (ERd vs Rd) 3 TOURMALINE (IRd vs Rd) 4 ENDEAVOR (Kd vs Vd) 5 CASTOR (DVd vs Vd) 6 1 line 2 lines 1 line 2 lines 1 line 2 lines 1 line 2 lines 1 line 2 lines 1 line 2 lines ( ) 0.69 ( ) 0.79 ( ) 0.68 ( ) ( ) 0.6 ( ) Favors novel-agent 1. Dimopoulos MA, et al. NEJM 2016;375: Stewart AK, et al. N Engl J Med 2015;372: Lonial S et al, NEJM 2015 Aug 13;373(7): Moreau P et al. N Engl J Med. 2016;374: Dimopoulos MA, et al. Lancet Oncology 2016; 17: Palumbo A et al, NEJM 2016; 6. Moreau P, ASH 2015 abst
36 What Are the Factors Influencing Our Decisions?: Cytogenetic Abnormalities POLLUX (DRd vs Rd) 4 ASPIRE (KRd vs Rd) 1 TOURMALINE (IRd vs Rd) 6 ENDEAVOR (Kd vs Vd) 2 CASTOR (DVd vs Vd) 5 SR HR SR HR SR HR SR HR SR HR HR (95% CI) 0.30 ( ) 0.44 ( ) 0.66 ( ) 0.70 ( ) ( ) 0.64 ( ) 0.29 ( ) 0.53 ( ) Favors novel-agent 1 1. Dimopoulos MA, et al. NEJM 2016;375: Stewart AK, et al. N Engl J Med 2015;372: Lonial S et al, NEJM 2015 Aug 13;373(7): Moreau P et al. N Engl J Med. 2016;374: Dimopoulos MA, et al. Lancet Oncology 2016; 17: Palumbo A et al, NEJM 2016; 6. Moreau P, ASH 2015 abst 727.
37 Go Online for More CCO Coverage of Myeloma! On-demand Webcast of this event at myeloma.org Capsule Summaries of all the key data for ASH 2017 Additional CME-certified slideset on myeloma with expert faculty commentary Online treatment decision aid with recommendations from 5 experts for your individual patients with myeloma ashsymposium2017.myeloma.org clinicaloptions.com/oncology clinicaloptions.com/myelomatool
Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions
Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions Friday, December 8, 2017 Atlanta, Georgia Friday Satellite Symposium preceding the 59th ASH Annual Meeting &
More informationCOMy Congress The case for IMids. Xavier Leleu. Hôpital la Milétrie, PRC, CHU, Poitiers, France
Xavier Leleu Hôpital la Milétrie, PRC, CHU, Poitiers, France The case for IMids COMy Congress 21 Disclosures Grants/research support: Amgen, Bristol-Myers Squibb, Celgene, Janssen, Millennium/Takeda, Novartis,
More informationLiving Well with Myeloma Teleconference Series Thursday, March 24 th :00 PM Pacific/5:00 PM Mountain 6:00 PM Central/7:00 PM Eastern
Living Well with Myeloma Teleconference Series Thursday, March 24 th 216 4: PM Pacific/5: PM Mountain 6: PM Central/7: PM Eastern Speakers Dr. Brian Durie, IMF Chairman Cedars Sinai Samuel Oschin Cancer
More informationHow to Integrate the New Drugs into the Management of Multiple Myeloma
How to Integrate the New Drugs into the Management of Multiple Myeloma Carol Ann Huff, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NCCN.org For Clinicians NCCN.org/patients For Patients
More informationAntibodies are a standard part of first relapse management in multiple myeloma (MM): Yes
Antibodies are a standard part of first relapse management in multiple myeloma (MM): Yes Ajay Nooka, MD MPH FACP Assistant Professor, Division of Bone Marrow Transplant Winship Cancer Institute, Emory
More informationMULTIPLE MYELOMA. TREATMENT in 2017 MC. VEKEMANS
MULTIPLE MYELOMA TREATMENT in 2017 MC. VEKEMANS NATURAL HISTORY of MM WHO SHOULD BE TREATED? DEFINITION MGUS Smouldering Multiple Myeloma Symptomatic Multiple Myeloma Monoclonal component (blood and/or
More informationUpdate on Multiple Myeloma Treatment
Update on Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director Cancer Science Institute,
More informationMyeloma update ASH 2014
Myeloma update ASH 2014 Updates in Newly Diagnosed Multiple Myeloma FIRST: effect of age on lenalidomide/dexamethasone vs MPT in transplantation-ineligible pts Phase III: MPT-T vs MPR-R in transplantation-ineligible
More informationGetting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions
Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions Friday, December 8, 2017 Atlanta, Georgia Friday Satellite Symposium preceding the 59th ASH Annual Meeting &
More informationDisclosures for Palumbo Antonio, MD
Disclosures for Palumbo Antonio, MD Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific Advisory Board o relevant conflicts of interest to declare o relevant
More informationDaratumumab: Mechanism of Action
Phase 3 Randomized Controlled Study of Daratumumab, Bortezomib and Dexamethasone (D) vs Bortezomib and Dexamethasone () in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): CASTOR* Antonio
More informationCurrent management of multiple myeloma. Jorge J. Castillo, MD Assistant Professor of Medicine Harvard Medical School
Current management of multiple myeloma Jorge J. Castillo, MD Assistant Professor of Medicine Harvard Medical School JorgeJ_Castillo@dfci.harvard.edu Multiple myeloma MM is a plasma cell neoplasm characterized
More informationNovel Treatment Advances and Approaches in Management of Relapsed/Refractory Multiple Myeloma
Novel Treatment Advances and Approaches in Management of Relapsed/Refractory Multiple Myeloma Ravi Vij, MD MBA Professor of Medicine Washington University School of Medicine Section of Stem Cell Transplant
More informationInitial Therapy For Transplant-Eligible Patients With Multiple Myeloma. Michele Cavo, MD University of Bologna Bologna, Italy
Initial Therapy For Transplant-Eligible Patients With Multiple Myeloma Michele Cavo, MD University of Bologna Bologna, Italy Treatment Paradigm for Autotransplant-Eligible Patients With Multiple Myeloma
More informationTREATING RELAPSED / REFRACTORY MYELOMA AT THE LEADING EDGE
TREATING RELAPSED / REFRACTORY MYELOMA AT THE LEADING EDGE PRESENTED BY: Pooja Chaukiyal MD Hematologist/Oncologist New York Oncology Hematology Albany, NY April 16, 2016 Background The prognosis for patients
More informationHighlights from EHA Mieloma Multiplo
Highlights from EHA Mieloma Multiplo Michele Cavo Istituto di Ematologia L. e A. Seràgnoli Alma Mater Studiorum Università degli studi di Bologna Firenze, 22-23 Settembre 27 Myeloma XI TE pathway 7 R :
More informationUpdates in Multiple Myeloma: 12 months in 10 minutes
Updates in Multiple Myeloma: 12 months in 10 minutes Aaron Rosenberg MD, MS Assistant Prof. Medicine UC Davis Comprehensive Cancer Center Division of Hematology and Oncology Outline Standard of care for
More informationUnmet Medical Needs and Latest Multiple Myeloma Treatment
Unmet Medical Needs and Latest Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director
More informationDaratumumab: Mechanism of Action
An Open-label, Randomised, Phase 3 Study of Daratumumab, Lenalidomide, and Dexamethasone (D) Versus Lenalidomide and Dexamethasone () in Relapsed or Refractory Multiple Myeloma (RRMM): POLLUX* Meletios
More informationNovel treatment strategies for multiple myeloma: a focus on oral proteasome inhibitors
Novel treatment strategies for multiple myeloma: a focus on oral proteasome inhibitors Antonio Palumbo M.D. Takeda Pharmaceuticals International AG Introduction Multiple genetically-distinct subclones
More informationCuring Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham
Curing Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham What is cure after all? Getting rid of it? Stopping treatment without
More informationCME Information LEARNING OBJECTIVES
CME Information LEARNING OBJECTIVES Identify patients with MM who have undergone autologous stem cell transplant and would benefit from maintenance lenalidomide. Counsel older patients (age 65 or older)
More informationNuove indicazioni e nuove terapie nel mieloma mul2plo
Nuove indicazioni e nuove terapie nel mieloma mul2plo Paola Tacche* Seràgnoli Ins3tute of Hematology Bologna University School of Medicine Mul2ple factors contribute to the clonal evolu2on and treatment
More informationTREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA
TREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA Ekarat Rattarittamrong, MD Division of Hematology Department of Internal Medicine Faculty of Medicine Chiang Mai University OUTLINE Overview of treatment
More informationStato dell arte: dalle opzioni terapeutiche alla strategia terapeutica nel 2017
Stato dell arte: dalle opzioni terapeutiche alla strategia terapeutica nel 2017 Elena Zamagni Istituto di Ematologia Seragnoli Università di Bologna Eligibility for ASCT Yes Induction: 3-drug regimens
More informationNovel Combination Therapies for Untreated Multiple Myeloma
Novel Combination Therapies for Untreated Multiple Myeloma Andrzej J. Jakubowiak, MD, PhD Director, Myeloma Program New York, NY, October 27, 201 Disclosures 2 Employee Consultant Major Stockholder Speakers
More informationIMiDs (Immunomodulatory drugs) and Multiple Myeloma
www.comtecmed.com/comy comy@comtecmed.com IMiDs (Immunomodulatory drugs) and Multiple Myeloma Xavier Leleu Service des Maladies du Sang Hôpital Huriez, CHRU, Lille, France www.comtecmed.com/comy comy@comtecmed.com
More informationUK MRA Myeloma XII Relapsed Intensive Study CI: Prof Gordon Cook
UK Myeloma Research Alliance Myeloma XII study (ACCoRD): Augmented Conditioning & Consolidation in Relapsed Disease UK MRA Myeloma XII Relapsed Intensive Study CI: Prof Gordon Cook Sponsor ID: Pending
More informationRole of consolidation therapy in Multiple Myeloma. Pieter Sonneveld. Erasmus MC Cancer Institute Rotterdam The Netherlands
Role of consolidation therapy in Multiple Myeloma Pieter Sonneveld Erasmus MC Cancer Institute Rotterdam The Netherlands Disclosures Research support : Amgen, Celgene, Janssen, Karyopharm Advisory Boards/Honoraria:
More informationRecent Advances in the Treatment & Management of Relapsed Refractory Multiple Myeloma.
Recent Advances in the Treatment & Management of Relapsed Refractory Multiple Myeloma. Ajay Nooka MD MPH Assistant Professor, Division of Bone Marrow Transplant Winship Cancer Institute, Emory University
More informationDARA Monotherapy Studies
Usmani, SZ. Blood. 26. http://dx.doi.org/.82/blood-26-3-752. Lokhorst HM, et al. N Engl J Med. 25;373(3):27-29. Lonial S, et al. Lancet. 25. I DARA Monotherapy Studies Baseline Characteristics Median (range)
More informationTreatment Advances in Multiple Myeloma: Expert Perspectives on Translating Clinical Data to Practice
Treatment Advances in Multiple Myeloma: Expert Perspectives on Translating Clinical Data to Practice Friday, December 2, 2016 San Diego, California This program is supported by educational grants from
More informationCOMy Congress A New Era of Advances in Myeloma. S. Vincent Rajkumar Professor of Medicine Mayo Clinic
A New Era of Advances in Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo Clinic Comprehensive
More informationCREDIT DESIGNATION STATEMENT
CME Information LEARNING OBJECTIVES Integrate emerging research information on the use of proteasome inhibitors and immunomodulatory agents to individualize induction treatment recommendations and maintenance
More informationPomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma. Lacy MQ et al. J Clin Oncol 2009;27(30):
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma Lacy MQ et al. J Clin Oncol 2009;27(30):5008-14. Introduction A curative therapy for multiple myeloma (MM) does
More informationTreatment of elderly multiple myeloma patients
SAMO Interdisciplinary Workshop on Myeloma March 30 th -31 st 2012, Seehotel Hermitage, Lucerne Treatment of elderly multiple myeloma patients Federica Cavallo, MD, PhD Federica Cavallo, MD, PhD Division
More informationConflict of Interest Disclosure Form
Conflict of Interest Disclosure Form NAME : Niels van de Donk MD-PhD AFFILIATION: University of California San Francisco. In accordance with the rules of the Health Care Inspectorate (IGZ), speakers are
More informationMultiple Myeloma What is New? Can we talk cure? Rafat Abonour, M.D.
Multiple Myeloma What is New? Can we talk cure? Rafat Abonour, M.D. Multiple Myeloma Facts Second most prevalent hematologic neoplasm Nearly 24, new cases diagnosed in the US per year and 11, worldwide
More informationMonoclonal antibodies and multiple myeloma Pr Philippe Moreau Nantes, France
Monoclonal antibodies and multiple myeloma Pr Philippe Moreau Nantes, France Disclosures Advisory boards and honoraria: Janssen, Takeda, Celgene, BMS, Novartis, Amgen Stockholder: no Rituximab + CHOP in
More informationTo Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors
To Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors James Berenson, MD Institute for Myeloma and Bone Cancer Research West Hollywood, CA Financial Disclosures Takeda, Celgene
More informationAdvances in the Management of Myeloma Parameswaran Hari, MD
Advances in the Management of Myeloma Parameswaran Hari, MD Armand J. Quick/William F. Stapp Professor of Hematology Director, Adult Blood and Marrow Transplant Program Froedtert Hospital Medical College
More informationMethods: Studies included in the analysis
Efficacy and safety of long-term ixazomib maintenance therapy in patients with newly diagnosed multiple myeloma not undergoing transplant: An integrated analysis of four phase 1/2 studies Meletios A. Dimopoulos,
More informationPhase I Study of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multicenter MMRC Clinical Trial
Phase I Study of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multicenter MMRC Clinical Trial Jonathan L. Kaufman, Todd Zimmerman, Cara A. Rosenbaum, Anuj Mahindra,
More informationMultiple Myeloma in 2016 Progress and Challenges DONNA E. REECE, M.D. PRINCESS MARGARET CANCER CENTRE 01 APRIL 2016
Multiple Myeloma in 2016 Progress and Challenges DONNA E. REECE, M.D. PRINCESS MARGARET CANCER CENTRE 01 APRIL 2016 Key Features of Myeloma Biology Myeloma is not one disease 1 At least 7 subtypes based
More informationApproach to the Treatment of Newly Diagnosed Multiple Myeloma. S. Vincent Rajkumar Professor of Medicine Mayo Clinic
Approach to the Treatment of Newly Diagnosed Multiple Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of
More informationDaratumumab: Mechanism of Action
Phase 3 Randomized Controlled Study of Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): CASTOR* Antonio
More informationCurrent treatment options for relapsed/refractory multiple myeloma in practice
Current treatment options for relapsed/refractory multiple myeloma in practice Professor Marίa-Victoria Mateos University Hospital of Salamanca, Salamanca, Spain Please note that discussion throughout
More informationRelapsed Myeloma Sequencing Treatments
Relapsed Myeloma Sequencing Treatments Noopur Raje, MD Director, Center for Multiple Myeloma MGH Cancer Center Professor of Medicine Harvard Medical School Disclosures Consultant /Advisory Board: Celgene,
More informationConsolidation and Maintenance therapy
University of Salamanca Consolidation and Maintenance therapy María-Victoria Mateos, MD, PhD University Hospital of Salamanca, Spain Disclosure form MVM has served as member of advisory boards or received
More informationAbstract. Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY, USA; 2 Hospital-12-de-Octubre, Madrid, Spain; 3
Daratumumab, Carfilzomib, and Dexamethasone (D-Kd) in Lenalidomiderefractory Patients with Relapsed Multiple Myeloma (MM): Subgroup Analysis of MMY11 Chari A, 1* Martinez-Lopez J, 2 Mateos M-V, 3 Bladé
More informationClinicalTrials.gov Identifier: NCT
Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Among Patients With to 3 Prior Lines of Therapy Based on
More informationMultiple Myeloma. Dr. Janet MacEachern BA, MD, FRCP(C) Grand River Regional Cancer Center Kitchener, Ontario
Multiple Myeloma Dr. Janet MacEachern BA, MD, FRCP(C) Grand River Regional Cancer Center Kitchener, Ontario Disclosures Relationships with financial sponsors: Grants/Research Support: n/a Speakers Bureau/Honoraria:
More informationBest of ASH 2017 DR. BRIAN DURIE. Brian GM Durie, MD Thursday, January 11, 2018
Best of ASH 2017 DR. BRIAN DURIE Brian GM Durie, MD Thursday, January 11, 2018 1 ASH Overview 2017 Total myeloma abstracts: 981 Important/Interesting: oral ~40 posters ~60 100 2 Which abstracts impact
More informationTherapie des Multiplen Myeloms Alles im Fluss? Peter Neumeister, MD Division Hematology Medical University Graz
Therapie des Multiplen Myeloms Alles im Fluss? Peter Neumeister, MD Division Hematology Medical University Graz 15.6.218 Newly Diagnosed Multiple Myeloma Transplant Eligible NDMM TE VCD is preferable to
More informationProgress in Multiple Myeloma
Progress in Multiple Myeloma Sundar Jagannath, MD Professor, New York Medical College Adjunct Professor, New York University St. Vincent s Comprehensive Cancer Center, NY Faculty Disclosure Advisory Board:
More informationAvances en el tratamiento del Mieloma Múltiple
University of Salamanca Avances en el tratamiento del Mieloma Múltiple María-Victoria Mateos University Hospital of Salamanca- IBSAL Salamanca. Spain Natural History of Multiple Myeloma Asymptomatic Symptomatic
More informationHighlights in multiple myeloma
3 CONGRESS HIGHLIGHTS Highlights in multiple myeloma P. Vlummens, MD SUMMARY Multiple myeloma (MM) remains a devastating disease, even in the era of novel agents. As such, the search for new treatment
More informationTreatment of Relapsed Myeloma Mayo Consensus
Treatment of Relapsed Myeloma Mayo Consensus Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo Clinic Comprehensive Cancer Center msmart Mayo Stratification
More informationA Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car- Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma
A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car- Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma Jatin J. Shah, MD 1, Edward A. Stadtmauer, MD 2, Rafat
More informationIs sustained triplet therapy the new standard of care in relapsed/refractory multiple myeloma?
Takeda Oncology-sponsored satellite symposium at the British Society for Haematology (BSH) 57 th Annual Scientific Meeting Is sustained triplet therapy the new standard of care in relapsed/refractory multiple
More informationMultiple Myeloma Brian Berryman, M.D. March 8 th, 2014
Multiple Myeloma 2014 Brian Berryman, M.D. March 8 th, 2014 Kyle, R. A. et al. Blood 2008;111:2962-2972 Updates in Multiple Myeloma CCO Independent Conference Coverage of the 2013 Annual Meeting of
More informationManaging Newly Diagnosed Multiple Myeloma
Managing Newly Diagnosed Multiple Myeloma 26 Jan 2018 Alfred Garfall, MD Assistant Professor of Medicine Diagnosis of Multiple Myeloma Traditional criteria: Monoclonal plasma cells + attributable CRAB
More informationManaging Major Adverse Events in Relapsed/Refractory Multiple Myeloma
Welcome to Managing Myeloma. I am Dr. Ajay Nooka. In today's presentation, I will discuss managing major adverse events in relapsed/refractory multiple myeloma. In this video, I will provide you with information
More informationStandard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant
Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant Pr Philippe Moreau University Hospital, Nantes, France MP: Standard of care until 2007 J Clin Oncol
More informationSTUDY DESIGN. VMP 6-week cycles, total of 9 cycles. Figure 2. Alcyone study design. Countries housing study sites are shaded in gold.
TPS8608 A Randomized Open-label Study of Bortezomib, Melphalan, And Prednisone (VMP) Versus Daratumumab () Plus VMP in Patients With Previously Untreated Multiple Myeloma (MM) Who Are Ineligible for High-dose
More informationMultiple Myeloma Transplant and Non-transplant Modalities
Multiple Myeloma Transplant and Non-transplant Modalities Sikander Ailawadhi, MD Associate Professor of Medicine Division of Hematology-Oncology Mayo Clinic, Jacksonville, Florida 15 th Annual Miami Cancer
More informationMAINTENANCE AND CONTINUOUS THERAPY OF MYELOMA. Myeloma Day 11/18/2017 Aric Hall, MD Assistant Professor UW School of Medicine & Public Health
MAINTENANCE AND CONTINUOUS THERAPY OF MYELOMA Myeloma Day 11/18/2017 Aric Hall, MD Assistant Professor UW School of Medicine & Public Health Disclosures I have no significant conflicts of interest to disclose.
More informationA Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car- Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma
A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car- Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma Jatin J. Shah, MD 1, Edward A. Stadtmauer, MD 2, Rafat
More informationUpcoming Therapies for Myeloma in Alberta. Dr Christopher Venner Cross Cancer Institute
Upcoming Therapies for Myeloma in Alberta Dr Christopher Venner Cross Cancer Institute Outline Diagnosis Hope for earlier diagnosis Prognosis Update in staging system for modern era highlights clear improvements
More informationTreatment Strategies for Transplant-ineligible NDMM Patients
1 Treatment Strategies for Transplant-ineligible NDMM Patients Thierry Facon, MD Professor of Hematology Service des Maladies du Sang University of Lille Lille, France Multiple Myeloma affects primarily
More informationIs autologous stem cell transplant the best consolidation after initial therapy?
Is autologous stem cell transplant the best consolidation after initial therapy? William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director,
More informationClinicalTrials.gov Identifier: NCT
Efficacy of Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma Based on Prior Lines of Therapy: Updated Analysis of CASTOR Maria-Victoria
More informationAn Open-label, Multicenter, Phase 1b Study of Daratumumab in Combination with Backbone Regimens in Patients with Multiple Myeloma
An Open-label, Multicenter, Phase 1b Study of Daratumumab in Combination with Backbone Regimens in Patients with Multiple Myeloma Philippe Moreau, MD; Maria-Victoria Mateos, MD, PhD; Joan Bladé,MD; Lotfi
More informationMultiple Myeloma: Induction, Consolidation and Maintenance Therapy
Multiple Myeloma: Induction, Consolidation and Maintenance Therapy James R. Berenson, MD Medical & Scientific Director Institute for Myeloma & Bone Cancer Research Los Angeles, CA Establish the Goals of
More informationTRATTAMENTO DEL PAZIENTE CON MIELOMA MULTIPLO AD ALTO RISCHIO ALLA RICADUTA
TRATTAMENTO DEL PAZIENTE CON MIELOMA MULTIPLO AD ALTO RISCHIO ALLA RICADUTA VITTORIO MENEGHINI UOC EMATOLOGIA Azienda Ospedaliera Universitaria Integrata - Verona MULTIPLE MYELOMA: CHANGING THE PARADIGM
More informationUpdates in the Treatment and Management of Relapsed/Refractory Multiple Myeloma
Updates in the Treatment and Management of Relapsed/Refractory Multiple Myeloma Rachid Baz, MD Associate Professor, Departments of Oncologic Sciences and Medicine University of South Florida Associate
More informationMultiple myeloma, 25 (45) years of progress. The IFM experience in patients treated with frontline ASCT. Philippe Moreau, Nantes
Multiple myeloma, 25 (45) years of progress The IFM experience in patients treated with frontline ASCT Philippe Moreau, Nantes Shibata T. Prolonged survival in a case of multiple myeloma treated with high
More informationH. Lee Moffitt Cancer Center and Research Institute, University of California, San Francisco & Tisch Cancer Institute, Mount Sinai School of Medicine
Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study Rachid Baz, Thomas
More informationTo Maintain or Not to Maintain? Lymphoma and Myeloma 2015 Waldorf Astoria Hotel, New York
To Maintain or Not to Maintain? Lymphoma and Myeloma 2015 Waldorf Astoria Hotel, New York Sundar Jagannath Director, Multiple Myeloma Program Tisch Cancer Institute Mount Sinai Medical Center Maintenance
More informationMultiple Myeloma: Approach to the Elderly
Multiple Myeloma: Approach to the Elderly Peter Anglin MD, FRCPC, MBA Stronach Regional Cancer Centre Newmarket, ON PMH Myeloma Day May 12, 2017 Peter Anglin MD Disclosures Speakers Bureau Advisory Boards
More informationDisclosures. Membership of Advisory Committees: Research Support/ PI: Celgene Corporation Millennium Pharmaceuticals Johnson & Johnson
Randomized, Open-Label Phase 1/2 Study of Pomalidomide Alone or in Combination With Low-Dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That
More informationInduction Therapy in Transplant Eligible MM 2 December Tontanai Numbenjapon, M.D.
Induction Therapy in Transplant Eligible MM 2 December 2017 Tontanai Numbenjapon, M.D. What we need from induction therapy in NDMM Depth of response: MRD-negative, scr, CR Longest response Acceptable toxicity
More informationConsolidation and maintenance therapy for transplant eligible myeloma patients
Consolidation and maintenance therapy for transplant eligible myeloma patients Teeraya Puavilai, M.D. Division of Hematology, Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University
More informationClínica Universidad de Navarra-CIMA, IDISNA, Pamplona, Spain. ClinicalTrials.gov Identifiers: NCT and NCT
Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated With Daratumumab in Combination With Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone
More informationHOW I TREAT RELAPSED/REFRACTORY MYELOMA? FOCUS ON FIRST RELAPSE
HOW I TREAT RELAPSED/REFRACTORY MYELOMA? FOCUS ON FIRST RELAPSE Evangelos Terpos, MD, PhD Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens,
More informationIs Transplant a Necessity or a Choice: Focus on the necessity for CR and MRD
Is Transplant a Necessity or a Choice: Focus on the necessity for CR and MRD Ajai Chari, MD Associate Professor of Medicine Director of Clinical Research Multiple Myeloma Program Mount Sinai Medical Center
More informationElotuzumab is a humanized monoclonal antibody designed to treat multiple myeloma (MM)
A Phase 2 Study of in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/ Refractory Multiple Myeloma: Updated Results Paul G. Richardson, 1,2 Sundar Jagannath, 2,3 Philippe
More informationMultiple Myeloma: ASH 2008
Multiple Myeloma: ASH 2008 Steven Coutre, M.D. Associate Professor of Medicine Division of Hematology Stanford University School of Medicine About These Slides These slides accompany CCO s comprehensive
More informationHow I Treat Transplant Eligible Myeloma Patients
How I Treat Transplant Eligible Myeloma Patients Michele Cavo Seràgnoli Institute of Hematology, Bologna University School of Medicine, Italy Podcetrtek, Slovene, April 14 th, 2012 NEW TREATMENT PARADIGM
More informationNew myeloma drugs improve response and extend survival
The JCSO Interview New myeloma drugs improve response and extend survival David H Henry, MD, a interviews Kenneth C Anderson, MD b a Department of Medicine, University of Pennsylvania Perelman School of
More informationCity of Hope, Duarte, CA, USA; 11 Columbia University Medical Center, New York, NY, USA. 1
Open-label, Multicenter, Phase 1b Study of Daratumumab in Combination With Pomalidomide and Dexamethasone in Patients With 2 Lines of Prior Therapy and Refractory or Relapsed and Refractory Multiple Myeloma
More informationContinuous Therapy as a Standard of Care CON. JL Harousseau Institut de Cancérologie de l Ouest Nantes Saint Herblain France
Continuous Therapy as a Standard of Care CON JL Harousseau Institut de Cancérologie de l Ouest Nantes Saint Herblain France 1 In France and in the IFM all debates 2 In France and in the IFM all debates
More informationNew Treatment Approaches in Myeloma in 2017
New Treatment Approaches in Myeloma in 2017 Jesus San-Miguel University of Navarra, Spain Multiple myeloma Second most common hematological malignancy Incidence: ~4/100,000 persons/year Prevalence: 60,000
More informationMultiple Myeloma in 2017 Making Sense of All of the Choices
Multiple Myeloma in 2017 Making Sense of All of the Choices TACOS March 2017 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael, MD, MEd, FRCPC, FACP Associate Dean, Mayo School
More informationAdvances in the Management of Myeloma Parameswaran Hari, MD
Advances in the Management of Myeloma Parameswaran Hari, MD Medical College of Wisconsin Milwaukee, WI What is the standard? Induction/Transplant/Maintenance UPDATED OS DATA from CALGB 100104 & IFM 2005-02
More informationMultiple Myeloma Highlights: 2016 ASH Annual Meeting Patient Webinar
2016 ASH Annual Meeting Patient Webinar January 11, 2017 1 Welcome and Introductions Anne Quinn Young, MPH Vice President, Development and Strategic Partnerships Multiple Myeloma Research Foundation 2
More informationCurrent Management of Multiple Myeloma. December 2012 Kevin Song MD FRCPC Leukemia/BMT Program of B.C.
Current Management of Multiple Myeloma December 2012 Kevin Song MD FRCPC Leukemia/BMT Program of B.C. Disclosures Honoraria Speaker Celgene, Janssen, Novartis Celgene, Janssen Research Support Celgene
More informationOncology Highlights ASCO 2011 MULTIPLE MYELOMA
Oncology Highlights ASCO 211 MULTIPLE MYELOMA July 211 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael, MD, MEd, FRCPC Staff Hematologist, Mayo Clinic Arizona Disclosures
More informationDisclosures. Consultancy, Research Funding and Speakers Bureau: Celgene Corporation, Millennium, Onyx, Cephalon
Pomalidomide With or Without Low-dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: Outcomes in Patients Refractory to Lenalidomide and Bortezomib Ravi Vij 1, Paul G. Richardson
More informationUpfront Therapy for Myeloma Tailoring Therapy across the Disease Spectrum
Upfront Therapy for Myeloma Tailoring Therapy across the Disease Spectrum S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic
More information